Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Piperazine-Functionalized Nanoparticles Enable Oral Insulin Delivery in Obese Mice.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Same author

Regenerative potential of nanoenabled collagen-polylactide scaffolds for osteochondral defect repair in rabbits.

Frontiers in bioengineering and biotechnology·2025

Same author

Rational design of anticancer multidrug nanosystems and their adaptation for glioblastoma treatment.

Drug delivery and translational research·2025

Same author

Modeling the human bladder tissue using three dimensional in vitro approaches as a tool for drug screening platforms.

Acta biomaterialia·2025

Same author

Corrigendum to 'Preclinical evaluation of several polymeric micelles identifies Soluplus®-docetaxel as the most effective candidate in multiple glioblastoma models' [Journal of Controlled Release (2025) 381:113616].

Journal of controlled release : official journal of the Controlled Release Society·2025

Same author

Nanocarrier-based intranasal drug delivery for enhanced neurological disorders treatment.

Drug delivery and translational research·2025

Search research articles

Related Experiment Video

Updated: Dec 27, 2025

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

Published on: March 4, 2017

The solid progress of nanomedicine.

João Pedro Martins¹, José das Neves², María de la Fuente³

¹Drug Research Program, Division of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Helsinki, FI-00014, Helsinki, Finland.

Drug Delivery and Translational Research

|March 7, 2020

Summary

This summary is machine-generated.

The National Cancer Institute (NCI) halted funding for Centers of Cancer Nanotechnology Excellence (CCNEs), sparking debate. This commentary discusses the impact on nanomedicine research and development.

Keywords:

Cancer therapy Clinical translation Nanomedicine Nanotechnology Reproducibility

More Related Videos

Author Spotlight: Advancements in Nanoparticle Technology for Drug Delivery and Immunotherapy

Author Spotlight: Advancements in Nanoparticle Technology for Drug Delivery and Immunotherapy

Published on: November 10, 2023

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

Related Experiment Videos

Last Updated: Dec 27, 2025

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

Published on: March 4, 2017

Author Spotlight: Advancements in Nanoparticle Technology for Drug Delivery and Immunotherapy

Author Spotlight: Advancements in Nanoparticle Technology for Drug Delivery and Immunotherapy

Published on: November 10, 2023

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

Area of Science:

Nanomedicine
Nanoscale science
Cancer research

Background:

The United States National Cancer Institute (NCI) recently ceased funding for the Centers of Cancer Nanotechnology Excellence (CCNEs).
This decision has prompted significant discussion within the scientific community, including editorial articles and commentary.
The Controlled Release Society's Nanomedicine and Nanoscale Delivery Focus Group has voiced its perspective on this matter.

Purpose of the Study:

To convey the views of the Nanomedicine and Nanoscale Delivery Focus Group board regarding the NCI's funding decision.
To broaden the discussion surrounding the implications of halting CCNE funding for cancer nanotechnology.
To provide expert commentary on the future of nanomedicine in cancer research.

Main Methods:

This is a commentary article, not an experimental study.
The main method involves presenting the collective viewpoint of the Focus Group board.
The discussion is informed by the context of the NCI's decision and related editorial articles.

Main Results:

The commentary expresses the board's perspective on the NCI's decision to defund CCNEs.
It highlights the importance of the CCNEs in advancing cancer nanotechnology.
The article serves as a platform for expert opinion on the consequences of this funding shift.

Conclusions:

The cessation of CCNE funding by the NCI warrants careful consideration and discussion within the nanomedicine field.
Continued support and strategic planning are crucial for the progress of cancer nanotechnology.
The Nanomedicine and Nanoscale Delivery Focus Group aims to foster dialogue and provide guidance on navigating these changes.